NASDAQ:ARDM - Aradigm Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aradigm Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.38 +0.23 (+150.03 %) (As of 01/27/2020 02:56 PM ET) Add Compare Today's Range$0.38Now: $0.38▼$0.3850-Day Range$0.15MA: $0.24▼$0.3852-Week Range$0.07Now: $0.38▼$2.33VolumeN/AAverage Volume97,091 shsMarket Capitalization$5.83 millionP/E RatioN/ADividend YieldN/ABeta1.57 ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARDM Previous Symbol CUSIPN/A CIK1013238 Webhttp://www.aradigm.com/ Phone510-265-9000Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.23Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$14.47 million Price / Sales0.40 Cash FlowN/A Price / Cash FlowN/A Book Value($0.83) per share Price / Book-0.46Profitability EPS (Most Recent Fiscal Year)($0.72) Net Income$-10,700,000.00 Net Margins-374.80% Return on EquityN/A Return on Assets-374.15%Miscellaneous EmployeesN/A Outstanding Shares15,220,000Market Cap$5.83 million Next Earnings DateN/A OptionableOptionable Receive ARDM News and Ratings via Email Sign-up to receive the latest news and ratings for ARDM and its competitors with MarketBeat's FREE daily newsletter. Aradigm (NASDAQ:ARDM) Frequently Asked Questions What is Aradigm's stock symbol? Aradigm trades on the NASDAQ under the ticker symbol "ARDM." How were Aradigm's earnings last quarter? Aradigm Co. (NASDAQ:ARDM) released its earnings results on Thursday, November, 15th. The company reported ($0.24) EPS for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.03. The company earned $0.28 million during the quarter. View Aradigm's Earnings History. Has Aradigm been receiving favorable news coverage? Press coverage about ARDM stock has been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aradigm earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Aradigm. Who are some of Aradigm's key competitors? Some companies that are related to Aradigm include ENDRA Life Sciences (NDRA), Digirad (DRAD), Vaso (VASO), Non-Invasive Monitoring Systems (NIMU), Nexeon Medsystems (NXNN), Reshape Lifesciences (RSLS), CHF Solutions (CHFS), ReShape Lifesciences (RSLSD), Viveve Medical (VIVE), Escalon Medical (ESMC), Trimedyne (TMED), Guided Therapeutics (GTHP), Magna-Lab (MAGAA), Newcardio (NWCI) and Echo Therapeutics (ECTE). What other stocks do shareholders of Aradigm own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aradigm investors own include Novavax (NVAX), Melco Resorts & Entertainment (MLCO), Synergy Pharmaceuticals (SGYP), IntelliPharmaCeutics Intl (IPCIF), Bio-Path (BPTH), Viking Therapeutics (VKTX), FTE Networks (FTNW), Helios and Matheson Analytics (HMNY), AcelRx Pharmaceuticals (ACRX) and Agenus (AGEN). Who are Aradigm's key executives? Aradigm's management team includes the folowing people: Dr. John M. Siebert, Exec. Chairman, Interim Principal Exec. Officer & Acting Principal Financial Officer (Age 79)Dr. Juergen Froehlich M.D., MBA, FCPh, Chief Medical Officer (Age 62)Dr. Igor Gonda, Consultant (Age 71)Ms. Nancy E. Pecota, Consultant (Age 59)Lisa Thomas, Corp. Controller What is Aradigm's stock price today? One share of ARDM stock can currently be purchased for approximately $0.38. How big of a company is Aradigm? Aradigm has a market capitalization of $5.83 million and generates $14.47 million in revenue each year. The company earns $-10,700,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. View Additional Information About Aradigm. What is Aradigm's official website? The official website for Aradigm is http://www.aradigm.com/. How can I contact Aradigm? Aradigm's mailing address is 3929 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-265-9000 or via email at [email protected] MarketBeat Community Rating for Aradigm (NASDAQ ARDM)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 185 (Vote Outperform)Underperform Votes: 262 (Vote Underperform)Total Votes: 447MarketBeat's community ratings are surveys of what our community members think about Aradigm and other stocks. Vote "Outperform" if you believe ARDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: Liquidity
